Trevi Therapeutics stock price target raised to $24 by H.C. Wainwright

The incremental signal is not the higher target; it is the removal of the most credible, best-capitalized early rival. That changes TRVI from a binary “can they win?” story to a “how large can the first real prescribing beachhead become?” story, which typically supports a higher multiple because commercialization uncertainty compresses less. The nuance is that the category may now form around one dataset, so any future miss on tolerability or magnitude of benefit becomes more important, not less.

The bigger second-order effect is funding and partnership optionality. A long cash runway reduces dilution risk and lets the market focus on execution rather than balance-sheet survival for the next 12-18 months, which should lower the discount rate applied to the pipeline. But the absence of a lead competitor can also slow market education; the revenue inflection may arrive later even if the eventual TAM is intact.

Consensus is probably over-reading this as clean white space. A rival’s retreat can reflect that chronic cough is harder to monetize than bulls assume, and smaller entrants may still need to spend heavily to educate prescribers and payers. I would treat TRVI as a relative long on pullbacks, not a momentum chase after the huge run; the thesis is falsified if FDA cadence slips, pivotal design weakens, or shares lose roughly $17.5 support before any meaningful 2027 visibility.